Denebian spotted fever
Denebian spotted fever is a human specific viral infection. It was first identified on Deneb (Deneb 1925) and due to its infectious nature, has spread through Deneb, The Marches, and Vland.
The virus can be spread through casual contact, and can survive airborne, though most standard anti-viral treatments are effective in eliminating the virus and preventing further spread.
Once the virus has been contracted, the symptoms appear in one to four days. Symptoms include nausea, high fever, delirium, and an outbreak of dark red spots on the face, torso, hands and arms. The disease has about an 80% fatality rate when left untreated, Symptomatic treatments reduce this to about 70%. The disease generally runs its course in six to eight days.
If the victim survives, the virus remains within their system. The disease then lies dormant until triggered by a combination of environmental factors. These factors include immune system suppression and exposure to artificial life support systems, though the exact nature has not been established. If the disease re-occurs, the person becomes infectious for a period of 4 to 7 days before symptoms reappear.
There are several vaccines for Denebian spotted fever, though they are not included in standard vaccine protocols.
SuSAG has produced an anti-viral specific to the Denebian spotted fever virus called GC96/B. The treatment reduces both the severity and duration of the outbreaks, and allows for a 95+% survival rate. The treatment does not eliminate the virus from the victim, and re-occurrences are still possible.
|
This article is incomplete meaning it lacks important features, structure, or content. More work needs to be done to make this a good article. This is step 4. in the article refinement process.
|